Ki-67 Antigen; A Valuable Prognostic Biomarker for Chronic Lymphocytic Leukemia

Document Type : Original Article (s)

Authors

1 Associate Professor of Hematology and Oncology, Department of Internal Medicine, School of Medicine AND Cancer Prevention Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Internal Medicine Specialist, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Chronic lymphocytic leukemia (CLL) is one of the most common blood malignancies. The chief cells involved in this malignancy are in the G0 phase of cell division and have no proliferative activity; however, what determines the severity and prognosis of this disease is cell proliferation. Ki-67 antigen is a nuclear protein that is present in all cell proliferative phases except G0. The present study was aimed to investigate the prognostic value of Ki-67 antigen expression in patients with CLL and their disease behavior.
Methods: The current cross-sectional study has been conducted on 50 CLL patients in 2017. The disease severity based on Rai's staging system, lymphadenopathy, organomegaly, and complete blood count and differentiation (CBC diff) were assessed at study initiation and within six months. Besides, Ki-67 antigen level was assessed via flow-cytometry. Eventually, the prognostic value of Ki-67 antigen to determine CLL prognosis was assessed utilizing Receiver operation curve (ROC)
Findings: The study population had the mean age of 64.12 ± 10.42 years old and predominantly consisted of males (68%), and had the mean Ki-67 antigen level of 2.48 ± 1.73 (%). Rai's stage deterioration to 3 or 4, organomegaly, white blood cells (WBC) doubling and concurrent Rai's staging deterioration and WBC doubling (P = 0.002) were directly associated with Ki-67 antigen levels. At the cut-point of 3.44%, Ki-67 antigen had the sensitivity and specificity of 87.5% an 92.9%, with area under the curve (AUC) 0f 0.940 (95%CI: 0.835-0.988;
P < 0.001).
Conclusion: According to this study, Ki-67 antigen is a valuable prognostic biomarker for CLL progression activity. Besides, at the cut-point of 3.44%, Ki-67 antigen had an acceptable predictive value for the progression manner of CLL disease.

Keywords

References

  1. Barrientos JC. Sequencing of chronic lymphocytic leukemia therapies. Hematology Am Soc Hematol Educ Program 2016; 2016(1): 128-36.
  2. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111(12): 5446-56.
  3. Delgado J, Nadeu F, Colomer D, Campo E. Chronic lymphocytic leukemia: From molecular pathogenesis to novel therapeutic strategies. Haematologica 2020; 105(9): 2205-17.
  4. Stilgenbauer S, Furman RR, Zent CS. Management of chronic lymphocytic leukemia. Am Soc Clin Oncol Educ Book 2015; 35(1): 164-75.
  5. Schleiss C, Carapito R, Fornecker LM, Muller L, Nicodeme P, Tahar O, et al. A core proliferative program induced by B-Cell receptor stimulation in chronic lymphocytic leukemia cells. Blood 2019; 134(Suppl 1): 3777.
  6. Patten PE, Ferrer G, Chen SS, Kolitz JE, Rai KR, Allen SL, et al. A detailed analysis of parameters supporting the engraftment and growth of chronic lymphocytic leukemia cells in immune-deficient mice. Front Immunol 2021; 12: 627020.
  7. Ponzoni M, Doglioni C, Caligaris-Cappio F. Chronic lymphocytic leukemia: the pathologist's view of lymph node microenvironment. Semin Diagn Pathol 2011; 28(2): 161-6.
  8. Burger JA. Treatment of chronic lymphocytic leukemia. N Engl J Med 2020; 383(5): 460-73.
  9. Scholzen T, Gerdes J. The Ki-67 protein: From the known and the unknown. J Cell Physiol 2000; 182(3): 311-22.
  10. Maffei R, Fiorcari S, Vaisitti T, Martinelli S, Benatti S, Debbia G, et al. Macitentan, a double antagonist of endothelin receptors, efficiently impairs migration and microenvironmental survival signals in chronic lymphocytic leukemia. Oncotarget 2017; 8(52): 90013-27.
  11. Sun X, Kaufman PD. Ki-67: more than a proliferation marker. Chromosoma 2018; 127(2): 175-86.
  12. Marcondes N, Fernandes F, Faulhaber G. Ki-67 expression in mature B-cell neoplasms: a flow cytometry study. Rev Assoc Med Bras 2018; 64(6): 525-9.
  13. Roth CG. Educational case: Chronic lymphocytic leukemia. Acad Pathol 2018; 5: 2374289518776011.
  14. Lenartova A. Chronic lymphocytic leukemia in Norway 1953-2012. [Thesis]. Oslo, Norway: University of Oslo; 2020.
  15. Kratzer W, Fritz V, Mason RA, Haenle MM, Kaechele V, Group RS. Factors affecting liver size: a sonographic survey of 2080 subjects. J Ultrasound Med 2003; 22(11): 1155-61.
  16. Konuş O, Ozdemir A, Akkaya A, Erbaş G, Celik H, Işik S. Normal liver, spleen, and kidney dimensions in neonates, infants, and children: evaluation with sonography. AJR Am J Roentgenol 1998; 171(6): 1693-8.
  17. Nørgaard CH, Søgaard NB, Biccler JL, Pilgaard L, Eskesen MH, Kjartansdottir TH, et al. Limited value of routine follow-up visits in chronic lymphocytic leukemia managed initially by watch and wait: A North Denmark population-based study. PloS One 2018; 13(12): e0208180.
  18. Tan MF, Zhang ZH, Yu JJ, Qu JH. Expression of ki-67 in chronic lymphocytic leukemia and its clinical significance [in Chinese]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2015; 23(2): 318-21.
  19. Elgammal MMA, El-Halawani NA, El-Sorady MES, El-Maghraby SM, Sallam GSM. Prognostic significance of BCL6 and KI67 in patients with chronic lymphocytic leukemia. Egypt J Haematol 2018; 43(4): 179.
  20. Gadallah H, Hegab H, Elsalakawy WA, Samra MA, Farweez BA, Saad AE. Predictive value of the proliferation marker Ki-67 in patients with acute leukemia undergoing hematopoietic stem cell transplantation. Egypt J Haematol 2018; 43(4): 222.
  21. Khoudoleeva O, Gretsov E, Barteneva N, Vorobjev I. Proliferative index and expression of CD38, Zap-70, and CD25 in different lymphoid compartments of chronic lymphocytic leukemia patients. Pathol Lab Med 2011; 3: 7-16.
  22. Qiu L, Xu J, Tang G, Wang SA, Lin P, Ok CY, et al. Mantle cell lymphoma with chronic lymphocytic leukemia-like features: a diagnostic mimic and pitfall. Hum Pathol 2022; 119: 59-68.
  23. Ciccone M, Agostinelli C, Rigolin G, Piccaluga PP, Cavazzini F, Righi S, et al. Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays. Leukemia 2012; 26(3): 499-508.
  24. Giné E, Martinez A, Villamor N, López-Guillermo A, Camos M, Martinez D, et al. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica 2010; 95(9): 1526-33.
Journal of Isfahan Medical School
Volume 40, Issue 693
1st Week,, January
January and February 2023
Pages 865-872

Files

History

  • Receive Date: 01 March 1401
  • Accept Date: 10 July 1401

Share

How to cite

Statistics